AR and breast carcinoma: By inducing immunogenic modulation in AR- breast carcinomas, particularly by reducing OPG expression, enzalutamide may not only provide monotherapy efficacy in this patient population but also could further impact TNBC patient care if combined with cancer immunotherapy.